Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Eldad Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Menachem Ben-Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Hanna Rosenbaum, MD, Riva Fineman, MD, Odelia Goor, MD, Diana Libster, MD, Zeev Blumenfeld, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2009) 114 (22): 1552.

https://doi.org/10.1182/blood.V114.22.1552.1552

Published: 2009

Journal Articles

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

Eldad J. Dann, MD, Ada Tamir, PhD, Ron Epelbaum, MD, Irit Avivi, MD, Menachem Ben-Shachar, MD, Diana Gaitini, MD, Jacob M. Rowe, MD, Rachel Bar-Shalom, MD

Blood (2008) 112 (11): 1452.

https://doi.org/10.1182/blood.V112.11.1452.1452

Published: 2008

Journal Articles

In Patients with Aggressive Non-Hodgkin Lymphoma Treated with CHOP Therapy the Rapidity of Early Response, as Determined by Residual FDG Uptake, Does Not Impact on the Overall Prognosis.

Eldad J. Dann, MD, Eyal Fuchs, Ada Tamir, PhD, Irit Avivi, MD, Diana Gaitini, MD, Ora Israel, MD, Jacob M. Rowe, MD, Rachel Bar-Shalom, MD

Blood (2007) 110 (11): 2328.

https://doi.org/10.1182/blood.V110.11.2328.2328

Published: 2007

Journal Articles

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Eldad J. Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Nissim Haim, MD, Irit Avivi, MD, Diana Gaitini, MD, Menachem Ben-Shachar, MD, Ora Israel, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2006) 108 (11): 4589.

https://doi.org/10.1182/blood.V108.11.4589.4589

Published: 2006

Journal Articles

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Eldad J. Dann, Rachel Bar-Shalom, Ada Tamir, Nissim Haim, Menachem Ben-Shachar, Irit Avivi, Tzila Zuckerman, Mark Kirschbaum, Odelia Goor, Diana Libster, Jacob M. Rowe, Ron Epelbaum

Blood (2006) 109 (3): 905–909.

https://doi.org/10.1182/blood-2006-04-019901

Published: 2006

Journal Articles

Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.

Eldad J. Dann, MD, Rachel Bar Shalom, MD, Nissim Haim, MD, Ada Tamir, Ph.D, Menachem Ben Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Mark Kirschbaum, MD, Odelia Goor, MD, Diana Libster, MD, Jacob M. Rowe, MD, Ron Apelbaum, MD

Blood (2005) 106 (11): 815.

https://doi.org/10.1182/blood.V106.11.815.815

Published: 2005

NARROW

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

In Patients with Aggressive Non-Hodgkin Lymphoma Treated with CHOP Therapy the Rapidity of Early Response, as Determined by Residual FDG Uptake, Does Not Impact on the Overall Prognosis.

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.

Email alerts

ASH Publications

American Society of Hematology

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

In Patients with Aggressive Non-Hodgkin Lymphoma Treated with CHOP Therapy the Rapidity of Early Response, as Determined by Residual FDG Uptake, Does Not Impact on the Overall Prognosis.

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only